Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02256969 · ClinicalTrials.gov registry record · Phase 4
Intraductal Meibomian Gland Probing Trial
A Phase 4 study, sponsored by Joseph B. Ciolino, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT02256969: Completed Phase 4 study, sponsored by Joseph B. Ciolino, MD.
NCT02256969 is a Phase 4 study that has completed, run by Joseph B. Ciolino, MD. The registered enrollment target is 45 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02256969, a Phase 4 study, has completed, sponsored by Joseph B. Ciolino, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or their symptoms. The investigators are also evaluating the effects of using two (2) post-procedural medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after the MGP procedure has an effect on its outcome.
Primary Outcome
A 12-question survey used to measure the symptoms of dry eye disease. Each of the 12 individual questions rate one symptom on a 0-4 scale, with 4 meaning that the symptom is present all of the time and 0 meaning the symptom is present none of the time. The overall ODSI score is calculated by adding all of the values from the 12 questions, multiplying that value by 25, and dividing the resulting value by the number of questions answered. This results in an overall scale that ranges from 0-100, wi
Interventions
- DRUG Blephamide
- DRUG GenTeal PM Night-Time
- PROCEDURE Meibomian Gland Probing
- PROCEDURE Sham Meibomian Gland Probing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
What the finished NCT02256969 record still lists
NCT02256969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 4 interventions - of which Blephamide is the first listed.
NCT02256969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02256969 about?
NCT02256969 is a clinical study titled "Intraductal Meibomian Gland Probing Trial". In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or t...
What is the current status of trial NCT02256969?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2014-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02256969?
The interventions under investigation include: Blephamide (DRUG), GenTeal PM Night-Time (DRUG), Meibomian Gland Probing (PROCEDURE), Sham Meibomian Gland Probing (PROCEDURE).
Who is sponsoring clinical trial NCT02256969?
This trial is sponsored by Joseph B. Ciolino, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02256969's enrollment target sits among peer trials
45 1354th of 2000 higher than 638 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia